|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Yescarta
gptkb:Immunomedics
Kite Pharma
|
|
gptkbp:awards
|
Best Places to Work
Innovative_Company_Award
Corporate_Social_Responsibility_Award
|
|
gptkbp:CEO
|
gptkb:Daniel_O'Day
|
|
gptkbp:clinicalTrials
|
COVID-19 treatments
HIV treatments
Hepatitis C treatments
Oncology treatments
|
|
gptkbp:communityInvolvement
|
Health education programs
Support for local charities
Volunteer_programs
|
|
gptkbp:employees
|
Health insurance
Retirement plans
500-1000
Paid time off
Employee stock options
|
|
gptkbp:financialPerformance
|
Revenue growth
R&D investment
Market capitalization
Profit_margin
|
|
gptkbp:focusArea
|
Antiviral drugs
|
|
gptkbp:founded
|
2001
|
|
gptkbp:headquarteredIn
|
gptkb:Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gilead Sciences Switzerland AG
|
|
gptkbp:industry
|
Biotechnology
|
|
gptkbp:market
|
Global
|
|
gptkbp:parentCompany
|
gptkb:Gilead_Sciences,_Inc.
|
|
gptkbp:partnerships
|
gptkb:Galapagos_NV
gptkb:GSK
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:philanthropy
|
gptkb:Gilead_Foundation
|
|
gptkbp:products
|
gptkb:Atripla
gptkb:Sovaldi
gptkb:Truvada
Biktarvy
Harvoni
|
|
gptkbp:regulatoryCompliance
|
gptkb:FDA
gptkb:Swissmedic
EMA
|
|
gptkbp:researchFocus
|
Inflammation
Oncology
HIV
Hepatitis C
|
|
gptkbp:subsidiary
|
gptkb:Gilead_Sciences,_Inc.
|
|
gptkbp:sustainabilityInitiatives
|
Community engagement
Diversity and inclusion
Environmental responsibility
|
|
gptkbp:website
|
www.gilead.com
|